Inventor
Ozlem Tureci
Inventor
Mainz, DE
Overview
Patents· 102 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Kprimary
C07KPeptides24%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations21%
A61KPreparations for medical, dental or toiletry purposes21%
G01NInvestigating or analysing materials by determining their chemical or physical properties11%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms10%
C12NMicroorganisms or enzymes8%
C12YEnzymes1%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests1%
G16BBioinformatics, i.e. information and communication technology [ict] specially adapted for genetic or protein-related data processing in computational molecular biology1%
G06FElectric digital data processing1%
PatentTitleYear
10,946,069Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancer202110,927,413Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis202110,919,974Antibodies for treatment of cancer expressing claudin 6202110,844,133Cancer therapy using CLDN6 target-directed antibodies in vivo202010,813,996Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer202010,745,477Antibodies specific for claudin 6 (CLDN6)202010,738,108Monoclonal antibodies against claudin-18 for treatment of cancer202010,724,103Identification of surface associated antigen FLJ31461 for tumor diagnosis and therapy202010,717,780Agents for treatment of claudin expressing cancer diseases202010,604,568Diagnosis and therapy of cancer involving cancer stem cells202010,596,256Monoclonal anti-GT 468 antibodies for treatment of cancer202010,526,387Tumor vaccination involving a humoral immune response against self-proteins202010,414,824Genetic products differentially expressed in tumors and the use thereof201910,370,423Claudin-6-specific immunoreceptors and T cell epitopes201910,314,890Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancer201910,302,647Identification of surface-associated antigens for tumor diagnosis and therapy201910,253,373Identification of tumor-associated markers for diagnosis and therapy201910,233,253Antibodies for treatment of cancer expressing claudin 6201910,174,104Monoclonal antibodies against claudin-18 for treatment of cancer201910,137,195Therapy involving antibodies against Claudin 18.2 for treatment of cancer201810,125,196Monoclonal antibodies for treatment of cancer201810,117,918Antigen-specific T cell receptors and T cell epitopes201810,106,800Modification of RNA, producing an increased transcript stability and translation efficiency201810,093,736Agents for treatment of claudin expressing cancer diseases201810,053,512Antibodies against claudin 18.2 useful in cancer diagnosis201810,036,753Identification of surface-associated antigens for tumor diagnosis and therapy201810,022,444Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer201810,017,564Monoclonal antibodies against claudin-18 for treatment of cancer20189,932,401Antibodies specific for claudin 6 (CLDN6)20189,919,036'Identification of tumor-associated antigens for diagnosis and therapy'20189,910,043'Identification of tumor-associated cell surface antigens for diagnosis and therapy'20189,902,778'Cancer therapy using CLDN6 target-directed antibodies in vivo'20189,809,815'Methods and compositions for diagnosis and treatment of cancer'20179,775,785'Antibody to genetic products differentially expressed in tumors and the use thereof'20179,770,487'Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic adenocarcinoma'20179,751,934'Monoclonal antibodies against claudin-18 for treatment of cancer'20179,733,251'Identification of tumour-associated cell surface antigens for diagnosis and therapy'20179,718,886'Cancer therapy using CLDN6 target-directed antibodies in vivo'20179,637,548'Methods and compositions for diagnosis and treatment of cancer'20179,637,794'Genetic products differentially expressed in tumors and use thereof'20179,617,321'Tumor vaccination involving a humoral immune response against self-proteins'20179,586,997'Antigen-specific T cell receptors and T cell epitopes'20179,533,043'Identification of surface-associated antigens for tumor diagnosis and therapy'20179,512,232'Antibodies against Claudin 18.2 useful in cancer diagnosis'20169,499,609'Monoclonal antibodies against claudin-18 for treatment of cancer'20169,486,519'Use of FLT3 ligand for enhancing immune responses in RNA immunization'20169,487,584'Antibodies specific for claudin 6 (CLDN6)'20169,475,867'Monoclonal antibodies for treatment of cancer'20169,476,055'Modification of RNA, producing an increased transcript stability and translation efficiency'20169,453,260'Genetic products differentially expressed in tumors and use thereof'20169,433,675'Combination therapy involving antibodies against claudin 18.2 for treatment of cancer'20169,321,842'Antibodies for treatment of cancer'20169,267,177'Identification of tumor-associated cell surface antigens for diagnosis and therapy'20169,255,131'Identification of surface-associated antigens for tumor diagnosis and therapy'20169,216,218'Monoclonal antibodies for treatment of cancer'20159,212,228'Monoclonal antibodies against claudin-18 for treatment of cancer'20159,194,004'Identification of surface-associated antigens for tumor diagnosis and therapy'20159,175,088'Identification of tumor-associated markers for diagnosing or monitoring ovarian cancer'20159,139,880'Identification of tumor-associated cell surface antigens for diagnosis and therapy'20159,139,639'Polynucleotides encoding an intracellular segment of CD40 and a constant region of an immunoglobulin heavy chain'20159,090,940'Identification of surface-associated antigens for tumor diagnosis and therapy'20159,061,007'Compositions and methods for therapy and diagnosis of cancer and cancer metastasis'20159,044,382'Genetic products differentially expressed in tumors and the use thereof'20158,975,375'Identification of tumor-associated antigens for diagnosis and therapy'20158,961,980'Monoclonal antibodies for treatment of cancer'20158,946,388'Monoclonal antibodies for treatment of cancer'20158,945,923'Antigen-specific clonal expansion of B cells'20158,840,902'Tumor vaccination involving a humoral immune response against self-proteins'20148,716,455'Genetic products differentially expressed in tumors and use thereof'20148,637,006'Recombinant vaccines and use thereof'20148,637,012'Genetic products differentially expressed in tumors and the use thereof'20148,586,047'Genetic products differentially expressed in tumors and the use thereof'20138,551,490'Genetic products differentially expressed in tumors and use thereof'20138,425,902'Monoclonal antibodies against claudin-18 for treatment of cancer'20138,399,210'Autoantigenes for improved diagnosis, prognosis and treatment of inflammatory neurological diseases'20138,354,104'Monoclonal antibodies for treatment of cancer'20138,178,653'Recombinant vaccines and use thereof'20128,168,427'Monoclonal antibodies against claudin-18 for treatment of cancer'20128,088,913'Compositions and methods for therapy and diagnosis of cancer'20128,088,588'Genetic products differentially expressed in tumors and the use of thereof'20127,875,424'Identification of tumour-associated cell surface antigens for diagnosis and therapy'20117,785,801'Identification of surface-associated antigens for tumor diagnosis and therapy'20107,527,933'Genetic products differentially expressed in tumors and the use thereof'20097,429,461'Genetic products differentially expressed in tumors and use thereof'20087,385,044'Isolated peptides which bind to MHC Class II molecules, and uses thereof'20087,270,819'Isolated nucleic acid molecules encoding isolated peptides which correspond to contiguous amino acids of an SSX molecule or NY-ESO-1 and uses thereof'20076,800,730'Isolated peptides which bind to MHC class II molecules, and uses thereof'20046,673,350'Tumor associated peptide and uses thereof'20046,548,064'Isolated peptides consisting of amino acid sequences found in SSX or NY-ESO-1 molecules, which bind to HLA molecules'20036,339,140'SSX family proteins'20026,338,947'Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith'20026,306,389'Isolated SCP proteins and uses thereof'20016,291,658'Isolated nucleic acid molecules encoding SSX family members and thereof'20016,287,756'Methods for determining presence of cancer in a sample by determining expression of an SSX gene'20016,274,145'Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof'20016,261,778'Isolated nucleic acid molecules which encode SCP proteins, and uses thereof'20016,239,256'Isolated muteins of proteins SCP-1, and compositions containing the mutein'20016,232,460'Isolated nucleic acid molecule which encodes an SCP-1 mutein'20016,214,983'Isolated nucleic acid molecules which encode SCP proteins'20016,140,050'Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith'20006,069,233'Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof'20005,888,751'Method for diagnosis and treating cancers, and methods for identifying pathogenic markers in a sample of normal cells'1999Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1999–2008Patents assigned to LUDWIG INST CANCER RES (18)· patent assignee history
1999–2008Based in Homburg/Saar, DE· patent location history
2000Based in Neunkirchen, DE· patent location history
2004–2021Based in Mainz, DE· patent location history
2008–2021Patents assigned to GANYMED PHARMACEUTICALS AG (56)· patent assignee history
2012–2018Patents assigned to SAHIN UGUR (32)· patent assignee history
2012–2020Patents assigned to BIONTECH AG (24)· patent assignee history
2012–2017Patents assigned to KOSLOWSKI MICHAEL (20)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| GANYMED PHARMACEUTICALS AG | 56 | 2008–2021 |
| SAHIN UGUR | 32 | 2012–2018 |
| BIONTECH AG | 24 | 2012–2020 |
| KOSLOWSKI MICHAEL | 20 | 2012–2017 |
| LUDWIG INST CANCER RES | 18 | 1999–2008 |
Locations
| Location | Patents | Span |
|---|---|---|
| Mainz, DE | 85 | 2004–2021 |
| Homburg/Saar, DE | 16 | 1999–2008 |
| Neunkirchen, DE | 1 | 2000 |